José María García-Acuña

José María García-Acuña

Auto-generated profile, based on publicly available information

José María García-Acuña

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain; Cardiology Department, Complejo Hospital Universitario de Santiago, Santiago de Compostela, Spain

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in JACC: Heart Failure
Verified
Journal Article
Closed access
MAManuel Almendro-Delia
Manuel Almendro-Delia
INIván J. Núñez-Gil
Iván J. Núñez-Gil
MLManuel Lobo
Manuel Lobo
MAMireia Andrés
Mireia Andrés
OVOscar Vedia
Oscar Vedia
MSM. Martínez Selles
M. Martínez Selles

17 December 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
Aitor UribarriAitor Uribarri
Aitor Uribarri
INIván J. Núñez-Gil
Iván J. Núñez-Gil
DCD. Aritza Conty
D. Aritza Conty
OVOscar Vedia
Oscar Vedia
MAManuel Almendro‐Delia
Manuel Almendro‐Delia
OIon behalf of the RETAKO Investigators
on behalf of the RETAKO Investigators
Background: Takotsubo syndrome ( TTS ) is an acute reversible heart condition initially believed to represent a benign pathology attributable to its self‐limiting clinical course; however, little is known about its prognosis based on different triggers. This study compared short‐ and long‐term outcomes between TTS based on different triggers, focusing on various physical triggering events. Methods and Results: We analyzed patients with a definitive TTS diagnosis recruited for the Spanish National Registry on TTS (RETAKO [Registry on Takotsubo Syndrome]). Short‐ and long‐term outcomes were compared between different groups according to triggering factors. A total of 939 patients were included. An emotional trigger was detected in 340 patients (36.2%), a physical trigger in 293 patients (31.2%), and none could be identified in 306 patients (32.6%). The main physical triggers observed were infections (30.7%), followed by surgical procedures (22.5%), physical activities (18.4%), episodes of severe hypoxia (18.4%), and neurological events (9.9%). TTS triggered by physical factors showed higher mortality in the short and long term, and within this group, patients whose physical trigger was hypoxia were those who had a worse prognosis, in addition to being triggered by physical factors, including age >70 years, diabetes mellitus, left ventricular eyection fraction <30% and shock on admission, and increased long‐term mortality risk. Conclusions: TTS triggered by physical factors could present a worse prognosis in terms of mortality. Under the TTS label, there could be as yet undiscovered very different clinical profiles, whose differentiation could lead to individual better management, and therefore the perception of TTS as having a benign prognosis should be generally ruled out.

1 January 2016 in Revista Espanola de Cardiologia
Verified
Journal Article
Closed access
EAEmad Abu-Assi
Emad Abu-Assi
ALAndrea López-López
Andrea López-López
VGVioleta González-Salvado
Violeta González-Salvado
ARAlfredo Redondo-Diéguez
Alfredo Redondo-Diéguez
CPCarlos Peña-Gil
Carlos Peña-Gil
JGJose R Gonzalez-Juanatey
Jose R Gonzalez-Juanatey

8 June 2017 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Closed access
Mario IannacconeMario Iannaccone
Mario Iannaccone
FDFabrizio D’ascenzo
Fabrizio D’ascenzo
PVPaolo Vadalà
Paolo Vadalà
SWStephen B Wilton
Stephen B Wilton
PNPatrizia Noussan
Patrizia Noussan
SKSasko Kedev
Sasko Kedev
Background: The prevalence and outcome of patients with cancer that experience acute coronary syndrome (ACS) have to be determined. Methods and results: The BleeMACS project is a multicentre observational registry enrolling patients with acute coronary syndrome undergoing percutaneous coronary intervention worldwide in 15 hospitals. The primary endpoint was a composite event of death and re-infarction after one year of follow-up. Bleedings were the secondary endpoint. 15,401 patients were enrolled, 926 (6.4%) in the cancer group and 14,475 (93.6%) in the group of patients without cancer. Patients with cancer were older (70.8±10.3 vs. 62.8±12.1 years, P<0.001) with more severe comorbidities and presented more frequently with non-ST-segment elevation myocardial infarction compared with patients without cancer. After one year, patients with cancer more often experienced the composite endpoint (15.2% vs. 5.3%, P<0.001) and bleedings (6.5% vs. 3%, P<0.001). At multiple regression analysis the presence of cancer was the strongest independent predictor for the primary endpoint (hazard ratio (HR) 2.1, 1.8–2.5, P<0.001) and bleedings (HR 1.5, 1.1–2.1, P=0.015). Despite patients with cancer generally being undertreated, beta-blockers (relative risk (RR) 0.6, 0.4–0.9, P=0.05), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (RR 0.5, 0.3–0.8, P=0.02), statins (RR 0.3, 0.2–0.5, P<0.001) and dual antiplatelet therapy (RR 0.5, 0.3–0.9, P=0.05) were shown to be protective factors, while proton pump inhibitors (RR 1, 0.6–1.5, P=0.9) were neutral. Conclusion: Cancer has a non-negligible prevalence in patients with acute coronary syndrome undergoing percutaneous coronary intervention, with a major risk of cardiovascular events and bleedings. Moreover, these patients are often undertreated from clinical despite medical therapy seems to be protective. Registration:The BleeMACS project (NCT02466854).

31 August 1996 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
JGJose R Gonzalez-Juanatey
Jose R Gonzalez-Juanatey
JGJosé María Garcá-Acuña
José María Garcá-Acuña
MFMarino Vega Fernandez
Marino Vega Fernandez
ACAntonio Amaro Cendón
Antonio Amaro Cendón
VFVictor Castelo Fuentes
Victor Castelo Fuentes
MPMiguel Gil de la Peña
Miguel Gil de la Peña

9 July 2012 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Closed access
EAEmad Abu-Assi
Emad Abu-Assi
SRSergio Raposeiras-Roubin
Sergio Raposeiras-Roubin
PLPamela Lear
Pamela Lear
PCPilar Cabanas-Grandío
Pilar Cabanas-Grandío
MGMar Girondo
Mar Girondo
JGJose R Gonzalez-Juanatey
Jose R Gonzalez-Juanatey
Haemorrhagic complications are strongly linked with adverse outcomes in acute coronary syndrome (ACS) patients. Various risk scores (RS) are available to predict bleeding risk in these patients. We compared the performance of three contemporary bleeding RS in ACS. We studied 4500 consecutive patients with ACS. We calculated the ACTION, CRUSADE, and Mehran et al. (2010) bleeding RS, and evaluated their performance for predicting their own major bleeding events and TIMI serious (major or minor) bleeding episodes, in patients with either non-ST-elevation ACS (NSTEACS) or ST-elevation myocardial infarction (STEMI). Calibration (Hosmer–Lemeshow test, HL) and discrimination (c-statistic) for the three RS were computed and compared. For RS-specific major bleeding, ACTION and CRUSADE showed the best prognostic discrimination in STEMI (c=0.734 and 0.791, respectively; p=0.04), and in NSTEACS (c=0.791 and 0.810; p=0.4); being CRUSADE significantly superior to Mehran et al. in both ACS types (p<0.05). All RS performed well in patients undergoing coronary arteriography using either a radial or femoral approach (all c≥0.718); however, their discriminative capacity was modest in patients not undergoing coronary arteriography and in those previously on oral anticoagulant (all c<0.70). For TIMI serious bleeding, ACTION and CRUSADE displayed the highest c-index values in both STEMI (0.724 and 0.703, respectively; p=0.3) and NSTEACS (c=0.733 and 0.744, respectively; p=0.6); however, calibration of ACTION was poor in both ACS types (HL p<0.05). Of contemporary bleeding RS, the CRUSADE score was found to be the most accurate quantitative tool for NSTEACS and STEMI patients undergoing coronary arteriography.